CT501

CT501 is an investigational bispecific antibody (BsAb) being developed by Alpha Biopharma for the treatment of autoimmune diseases. As a bispecific therapeutic, it is engineered to simultaneously bind to two distinct antigens or epitopes, a design intended to provide superior clinical efficacy or a more targeted safety profile compared to conventional monoclonal antibodies. While the specific molecular targets of CT501 have not been publicly disclosed by the developer, the program represents a key component of Alpha Biopharma's biologics pipeline, which also includes mRNA-based therapies and CAR-T cell treatments. The drug is currently in the early stages of development for undisclosed autoimmune indications.